Beleodaq

Chemical Namebelinostat
Dosage FormInjection (intravenous; 500mg)
Drug ClassInhibitors
SystemBlood
CompanyOxneo
Approval Year2014

Indication

  • For the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Beleodaq (belinostat) Prescribing Information 2014Spectrum Pharmaceuticals, Inc., Irvine, CA